FDA Approves First Therapy to Reduce Pancreatitis Risk - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves First Therapy to Reduce Pancreatitis Risk

In two placebo-controlled trials, triglyceride levels declined by up to 72% compared with placebo.

  • By

  • Kathryn Wighton

  • June 24, 2026

  • 2 min

Share

Clinical Report: FDA Approves First Therapy to Reduce Pancreatitis Risk

Overview

The FDA has approved olezarsen (Tryngolza) to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia. This approval is based on two randomized trials.

Background

Severe hypertriglyceridemia is defined as fasting triglyceride levels of at least 500 mg/dL. The approval of olezarsen represents a new therapeutic option for managing this condition.

Data Highlights

Trial50 mg Dose Reduction80 mg Dose Reduction
Trial 163%72%
Trial 249%55%

Key Findings

  • Olezarsen is approved to reduce triglycerides and pancreatitis risk in severe hypertriglyceridemia.
  • Mean baseline triglyceride levels in trials were 1,116 mg/dL.
  • Reductions in triglyceride levels were observed: 63% and 72% in Trial 1, and 49% and 55% in Trial 2.
  • A pooled analysis indicated a lower incidence of acute pancreatitis with olezarsen compared to placebo.
  • Common adverse reactions included injection-site reactions and increased liver enzyme levels.
  • Healthcare providers are advised to monitor liver enzymes before and during treatment.

Clinical Implications

Healthcare providers should monitor liver enzyme elevations before and during treatment.

Conclusion

Olezarsen has been approved for managing severe hypertriglyceridemia.

Related Resources & Content

  1. US Food and Drug Administration, FDA, 2024 -- FDA Approves First Therapy to Reduce Pancreatitis Risk
  2. The New Gastroenterologist — Endoscopic Sphincterotomy of the Minor Papilla Does Not Decrease Risks in Patients with Pancreas Divisum
  3. conexiant — FDA Approves Device for Pancreas Care
  4. conexiant — GLP-1 RAs Show Mixed Pancreatitis Risk
  5. Surgical Endoscopy — Efficacy of intravenous parecoxib in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial
  6. Endoscopic Sphincterotomy of the Minor Papilla Does Not Decrease Risks in Patients with Pancreas Divisum
  7. FDA Approves Device for Pancreas Care
  8. GLP-1 RAs Show Mixed Pancreatitis Risk
  9. TRYNGOLZA (olezarsen) injection, for subcutaneous use
  10. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation
  11. BRIDGE-TIMI 73a: Novel Olezarsen Reduces Triglycerides, ApoC3, ApoB Levels - American College of Cardiology

Original Source(s)

FDA Approves First Therapy to Reduce Pancreatitis Risk

  • by Kathryn Wighton

  • June 24, 2026

Related Content

4 societies redefine women's heart care

New multisociety guidance identifies menstrual irregularities as potential early markers of cardiovascular risk, extending prevention efforts into adolescence.

Depression, anxiety symptoms may be common in T1D

National survey data show a greater mental health symptom burden among adults with type 1 diabetes vs. those with type 2 diabetes or no diabetes.

OM-89 may curb postantibiotic E coli regrowth

Lysosomal activation and increased intracellular antibiotic accumulation accompanied reduced bacterial regrowth across mouse and human bladder epithelial models.